相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis
T. Komiya et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
CNS vasculitis in a patient with MS on daclizumab monotherapy
Joan Ohayon et al.
NEUROLOGY (2013)
Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor
Jan Thoene et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial
William Stohl et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis
Ernst-Wilhelm Radue et al.
ARCHIVES OF NEUROLOGY (2012)
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial
W. Rigby et al.
ARTHRITIS AND RHEUMATISM (2012)
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis
Roland Martin
CLINICAL IMMUNOLOGY (2012)
Immune mechanisms of new therapeutic strategies in MS - Teriflunomide
Malte C. Claussen et al.
CLINICAL IMMUNOLOGY (2012)
Rituximab and Multiple Sclerosis
Dimitrios K. Kitsos et al.
CLINICAL NEUROPHARMACOLOGY (2012)
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis
E. J. Fox et al.
EUROPEAN JOURNAL OF NEUROLOGY (2012)
Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells
Jun-Min Li et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2012)
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
Grant A. Hill-Cawthorne et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial
David H. Miller et al.
LANCET NEUROLOGY (2012)
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design
Edward Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years
Christian Confavreux et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Teriflunomide added to interferon-β in relapsing multiple sclerosis A randomized phase II trial
M. S. Freedman et al.
NEUROLOGY (2012)
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
A. J. Coles et al.
NEUROLOGY (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Ralf A. Linker et al.
BRAIN (2011)
Proteinuria with fumaric acid ester treatment for psoriasis
S. Ogilvie et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2011)
Recent insights into the mechanism of action of glatiramer acetate
Mrinalini Kala et al.
JOURNAL OF NEUROIMMUNOLOGY (2011)
Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis
Per Soelberg Sorensen
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Insight into the mechanism of laquinimod action
W. Brueck et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes
Alasdair J. Coles et al.
LANCET NEUROLOGY (2011)
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
Bhupendra Khatri et al.
LANCET NEUROLOGY (2011)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
Ludwig Kappos et al.
LANCET NEUROLOGY (2011)
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy
Simone C. Wuest et al.
NATURE MEDICINE (2011)
Oral laquinimod treatment in multiple sclerosis
O. Fernandez
NEUROLOGIA (2011)
Intrathecal effects of daclizumab treatment of multiple sclerosis
B. Bielekova et al.
NEUROLOGY (2011)
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone
V. Martinelli et al.
NEUROLOGY (2011)
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
M. Cossburn et al.
NEUROLOGY (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2010)
Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
Laura Piccio et al.
ARCHIVES OF NEUROLOGY (2010)
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Jerold Chun et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Alemtuzumab and multiple sclerosis: therapeutic application
Alireza Minagar et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Sara A. J. Thompson et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis
Christiane Wegner et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In-vitro high-throughput gene expression study
M. Gurevich et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. (vol 9, pg 381, 2010)
D. Wynn et al.
LANCET NEUROLOGY (2010)
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
David B. Clifford et al.
LANCET NEUROLOGY (2010)
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate
C. Ford et al.
MULTIPLE SCLEROSIS (2010)
Fingolimod is a potential novel therapy for multiple sclerosis
Orhan Aktas et al.
NATURE REVIEWS NEUROLOGY (2010)
Mitoxantrone and cytotoxic drugs' mechanisms of action
Timothy Vollmer et al.
NEUROLOGY (2010)
Monoclonal antibodies in MS Mechanisms of action
Bibiana Bielekova et al.
NEUROLOGY (2010)
Interferon-β mechanisms of action in multiple sclerosis
Suhayl Dhib-Jalbut et al.
NEUROLOGY (2010)
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
James J. Marriott et al.
NEUROLOGY (2010)
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis - A 52-week phase II trial
R. T. Naismith et al.
NEUROLOGY (2010)
Ibudilast in relapsing-remitting multiple sclerosis A neuroprotectant?
F. Barkhof et al.
NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Daniel Wynn et al.
LANCET NEUROLOGY (2010)
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases (vol 9, pg 438, 2010)
D. B. Clifford et al.
LANCET NEUROLOGY (2010)
Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis
Olaf Stuve et al.
ARCHIVES OF NEUROLOGY (2009)
Regulatory T Cells Are Reduced During Anti-CD25 Antibody Treatment of Multiple Sclerosis
Unsong Oh et al.
ARCHIVES OF NEUROLOGY (2009)
Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis
Bibiana Bielekova et al.
ARCHIVES OF NEUROLOGY (2009)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Kenneth R. Carson et al.
BLOOD (2009)
Rediscovering alemtuzumab: current and emerging therapeutic roles
John G. Gribben et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Melanoma following treatment with alemtuzumab for multiple sclerosis
A. A. Pace et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Ocrelizumab: a step forward in the evolution of B-cell therapy
Fariha Kausar et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
Yanping Hu et al.
IMMUNOLOGY (2009)
A review of the current use of rituximab in autoimmune diseases
Hakan M. Guercan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2009)
Regulatory Properties of Copolymer I in Th17 Differentiation by Altering STAT3 Phosphorylation
Chunhua Chen et al.
JOURNAL OF IMMUNOLOGY (2009)
Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis
Jean E. Merrill et al.
JOURNAL OF NEUROLOGY (2009)
Estrogen treatment in multiple sclerosis
Stefan M. Gold et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis
H. -P. Hartung
NERVENARZT (2009)
Safety profile of Tysabri: international risk management plan
P. Iaffaldano et al.
NEUROLOGICAL SCIENCES (2009)
Mitoxantrone: benefits and risks in multiple sclerosis patients
V. Martinelli et al.
NEUROLOGICAL SCIENCES (2009)
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2008)
Leflunomide-Associated Progressive Multifocal Leukoencephalopathy
Megan Rahmlow et al.
ARCHIVES OF NEUROLOGY (2008)
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Rituximab: Beyond simple B cell depletion
A. Kessel et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2008)
Monoclonal antibodies in the therapy of multiple sclerosis An overview
P. S. Rommer et al.
JOURNAL OF NEUROLOGY (2008)
Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis
C. L. Hirst et al.
JOURNAL OF NEUROLOGY (2008)
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
G. Comi et al.
LANCET (2008)
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
Ludwig Kappos et al.
LANCET (2008)
Getting specific: monoclonal antibodies in multiple sclerosis
Andreas Lutterotti et al.
LANCET NEUROLOGY (2008)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment
Charlotte Magdelaine-Beuzelin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Daclizumab
Marcus Mottershead et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Diminished myelin-specific T cell activation associated with increase in CTLA4 and Fas molecules in multiple sclerosis patients treated with IFN-β
Dannie E. M. Hallal-Longo et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2007)
Daclizumab phase II trial in relapsing and remitting multiple sclerosis - MRI and clinical results
J. W. Rose et al.
NEUROLOGY (2007)
Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Tb1/Th2 cytokine production
James T. Snyder et al.
BLOOD (2007)
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
D. H. Miller et al.
NEUROLOGY (2007)
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
Roberta Magliozzi et al.
BRAIN (2007)
Drug Insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis
Ronald P. Taylor et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2007)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L. Kappos et al.
NEUROLOGY (2006)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells
Tomoko Watanabe et al.
CLINICAL IMMUNOLOGY (2006)
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration
S. Schilling et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
Oral fumaric acid esters for the treatment of active multiple sclerosis:: an open-label, baseline-controlled pilot study
S. Schimrigk et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis
Samy Suissa et al.
ARTHRITIS AND RHEUMATISM (2006)
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-β k.o. and wild type mice
A Runström et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
PW O'Connor et al.
NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
TA Yousry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The window of therapeutic opportunity in multiple sclerosis
AJ Coles et al.
JOURNAL OF NEUROLOGY (2006)
Mitoxantrone treatment of multiple sclerosis: Safety considerations
RG Pratt et al.
NEUROLOGY (2005)
Drug Insight: using monoclonal antibodies to treat multiple sclerosis
R Hohlfeld et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2005)
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
AL Cox et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Detoxication enzyme inducers modify cytokine production in rat mixed glial cells
A Wierinckx et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator
H Tuvesson et al.
DRUG METABOLISM AND DISPOSITION (2005)
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity
H Nückel et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
C Polman et al.
NEUROLOGY (2005)
Subcutaneous recombinant - Interferon-beta-1a (Rebif((R))) - A review of its use in relapsing-remitting multiple sclerosis
D Murdoch et al.
DRUGS (2005)
Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in downregulated Th1 lymphocyte responses
NHR Litjens et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
G Hale et al.
BLOOD (2004)
Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody
JW Rose et al.
ANNALS OF NEUROLOGY (2004)
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats
HS Yang et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - mechanisms independent of pyrimidine depletion
T Korn et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells
M Stanglmaier et al.
ANNALS OF HEMATOLOGY (2004)
Pharmacokinetics of oral fumarates in healthy subjects
NHR Litjens et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Glatiramer acetate (Copaxone®) therapy for multiple sclerosis
S Dhib-Jalbut
PHARMACOLOGY & THERAPEUTICS (2003)
Dimethylfumarate is a potent inducer of apoptosis in human T cells
F Treumer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature
K Warnatz et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephomyelitis
C Brunmark et al.
JOURNAL OF NEUROIMMUNOLOGY (2002)
Dimethylfumarate inhibits TNF-induced nuclear entry of NF-κB/p65 in human endothelial cells
R Loewe et al.
JOURNAL OF IMMUNOLOGY (2002)
Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue
LP Zou et al.
NEUROPHARMACOLOGY (2002)
Mechanisms of action of glatiramer acetate in multiple sclerosis
O Neuhaus et al.
NEUROLOGY (2001)
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
G Comi et al.
ANNALS OF NEUROLOGY (2001)
Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes
DJ Miljkovic et al.
BRAIN RESEARCH (2001)
Pharmacokinetics of CAMPATH-1H in BMT patients
P Rebello et al.
CYTOTHERAPY (2001)
VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis
PA Muraro et al.
JOURNAL OF NEUROIMMUNOLOGY (2000)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
LD Jacobs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Linomide in relapsing and secondary progressive MS - Part I: Trial design and clinical results
JH Noseworthy et al.
NEUROLOGY (2000)
The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review
M Schattenkirchner
IMMUNOPHARMACOLOGY (2000)
分享论文
